{"url_path":"/sec/teva/8-k/2026-09-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/818686/0001193125-26-389264-index.html","accession_number":"0001193125-26-389264","cik":"0000818686","ticker":"TEVA","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","edgar_url":"https://www.sec.gov/Archives/edgar/data/818686/0001193125-26-389264-index.html","primary_entity_key":"0000818686","primary_entity_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD"},"word_count":138,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits\n\n(d) Exhibits\n\n \n\nExhibit\n  \n \n\n 1.1\n  \n[Underwriting Agreement, dated as of September 9, 2026, among the Issuers, the Company, BNP PARIBAS, BNP Paribas Securities Corp., Citigroup Global Markets Europe AG, Citigroup Global Markets Inc., Goldman Sachs Bank Europe SE, J.P. Morgan SE and J.P. Morgan Securities LLC, as representatives for the underwriters named in Schedule 1 annexed thereto.](d81245dex11.htm)\n\n99.1\n  \n[Press Release dated September 10, 2026.](d81245dex991.htm)\n\n104\n  \nThe cover page of this Current Report on Form 8-K, formatted in Inline XBRL.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDate: September 11, 2026\n\n \n\nTEVA PHARMACEUTICAL INDUSTRIES LIMITED\n\nBy:\n \n\n/s/ Eli Kalif\n\nName:\n \nEli Kalif\n\nTitle:\n \nExecutive Vice President, Chief Financial Officer\n\n3"}